A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX¿147 in Adults With APOL1-dependent Focal Segmental Glomerulosclerosis

Administered By

Awarded By

Start/End

  • June 4, 2020 - June 3, 2025